Maravai LifeSciences Holdings, Inc. Class A Common Stock
Here’s whether Maravai LifeSciences Holdings, Inc. Class A Common Stock (MRVI) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Neutral.
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); strong 1-year return of +97.1%. Concerns: 50-day MA is falling (-2.08% over 10 days); RSI 75 — overbought, elevated pullback risk; 3-month momentum negative (-13.5%). Currently 17.4% off its 52-week high. Score: +1/7.
MRVI is in a confirmed uptrend, trading above both its 50-day ($3.19) and 200-day ($3.10) moving averages. With an RSI of 74.8, momentum has stretched into overbought territory — short-term pullbacks are common from these levels. The 1-year return of +97.1% compares to +35.1% for SPY (beat the market by 62.0%).